What is Rituxan?
Rituxan (rituximab) is a monoclonal antibody designed to recognize specific proteins found on the surface of lymphoma cells. It may be used alone (monotherapy) or in combination with other chemotherapeutic drugs to treat non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Other uses include treatment of autoimmune diseases such as rheumatoid arthritis.
How Does it Work?
The monoclonal antibody recognizes the surface protein and locks onto the cancer cells, thus triggering the body’s immune system to attack and destroy these cells. Rituxan is given by infusion into a vein over about six hours, depending on the patient’s tolerance of the drug.